Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.

[1]  R. Burger,et al.  Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Burger,et al.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Roger B. Lee,et al.  Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. , 2003, Gynecologic oncology.

[5]  K. Swenerton,et al.  Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Dimopoulos,et al.  Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. , 2000, Gynecologic oncology.

[7]  M. Hatae,et al.  [Evaluation of paclitaxel and carboplatin in patients with endometrial cancer]. , 2000, Gan to kagaku ryoho. Cancer & chemotherapy.

[8]  R. Edwards,et al.  A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report. , 1997, Seminars in oncology.

[9]  T. Olencki,et al.  Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors , 1997, Cancer.

[10]  D. Mutch,et al.  A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.

[11]  J. Glick,et al.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P S Schein,et al.  Amifostine‐mediated protection of normal bone marrow from cytotoxic chemotherapy , 1993, Cancer.

[13]  R. O’Toole,et al.  Carboplatin therapy in advanced endometrial cancer , 1990, Obstetrics and gynecology.

[14]  G. Sutton,et al.  Phase II trial of clsplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A gynecologic oncology group study , 1989 .

[15]  J. Buckner,et al.  Phase II evaluation of carboplatin in advanced endometrial carcinoma. , 1988, Journal of the National Cancer Institute.

[16]  J. Edmonson,et al.  Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. , 1987, Gynecologic oncology.

[17]  J. Herson,et al.  Cisplatin Chemotherapy for Disseminated Endometrial Cancer , 1982, Obstetrics and gynecology.

[18]  C. Cohen,et al.  Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammine platinum (II) after intensive prior therapy. , 1980, Gynecologic oncology.

[19]  R. Capizzi.  The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). , 1996, European journal of cancer.

[20]  R. Bukowski,et al.  Phase I study of WR-2721 and carboplatin. , 1993, European journal of cancer.

[21]  J. Thigpen,et al.  Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. , 1979, Cancer treatment reports.